Head to Head Comparison: Precision BioSciences (NASDAQ:DTIL) and Silence Therapeutics (NASDAQ:SLN)

Silence Therapeutics (NASDAQ:SLN – Get Free Report) and Precision BioSciences (NASDAQ:DTIL – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.

Risk and Volatility

Silence Therapeutics has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Silence Therapeutics and Precision BioSciences, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silence Therapeutics 1 4 2 0 2.14
Precision BioSciences 1 0 4 0 2.60

Silence Therapeutics presently has a consensus target price of $24.00, suggesting a potential upside of 21.22%. Precision BioSciences has a consensus target price of $32.25, suggesting a potential upside of 360.06%. Given Precision BioSciences’ stronger consensus rating and higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Silence Therapeutics.

Profitability

This table compares Silence Therapeutics and Precision BioSciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Silence Therapeutics -8,943.86% -102.72% -43.70%
Precision BioSciences -96.73% -56.69% -27.63%

Insider and Institutional Ownership

98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by insiders. Comparatively, 2.7% of Precision BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Silence Therapeutics and Precision BioSciences”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Silence Therapeutics $560,000.00 2,197.22 -$88.61 million ($1.07) -18.50
Precision BioSciences $34.26 million 5.72 -$45.72 million ($1.24) -5.65

Precision BioSciences has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Summary

Precision BioSciences beats Silence Therapeutics on 9 of the 13 factors compared between the two stocks.

About Silence Therapeutics

(Get Free Report)

Silence Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce production of specific disease-related proteins. Its proprietary mRNAi GOLD platform is designed to create small interfering RNA (siRNA) medicines, including treatments that target genes expressed in the liver. The company’s research and development programs have included zerlasiran, which targets lipoprotein(a), a risk factor for cardiovascular disease, and divesiran, investigated for blood disorders.

About Precision BioSciences

(Get Free Report)

Precision BioSciences is a biotechnology company developing gene-editing therapies using its proprietary ARCUS platform. The platform is designed to make targeted changes to DNA and is being applied to investigational treatments for genetic and infectious diseases. The company’s programs include PBGENE-HBV, an investigational therapy designed to target hepatitis B virus DNA, and PBGENE-DMD, a gene-editing program for Duchenne muscular dystrophy. These candidates remain in development and are not approved treatments.

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.